Description
The legionella testing market is anticipated to be valued at USD 241.5 million in 2021 and is expanded to grow at a significant CAGR of 9.7% over 2022-2028. Legionella bacterial species are present in freshwater reservoirs and are responsible for legionnaire’s disease, a respiratory ailment. The market is anticipated to increase fast during the projected period due to the increased incidence and prevalence of this disease, pushing up demand for testing kits. Furthermore, the rising incidence of hospital-acquired legionella infection and increased testing frequency in these facilities due to stringent regulations will drive demand for such effective products in the near future. The presence of diverse species in water reservoirs like ponds, lakes, swimming pools, warm water showers, and commercial building water supply pipes is increasing health hazards. Exposure to legionellosis outbreaks increases the risk of morbidity and mortality. Thus, stringent monitoring of water reservoirs and the launch of rapid testing methods for onsite water testing are anticipated to promote Legionella testing market growth. In the Legionella Testing Market, the Urinary Antigen Test (UAT) Segment is Expected to Hold a Major Market Share. This test category is predicted to develop rapidly over the projection period due to distinct advantages such as detecting whole serogroups associated with legionella and quick testing. Due to the expensive cost of PCR procedures, their general application in the current economy is limited.
Recent Market Developments:
In December 2021, QUIDEL CORPORATION signs a definitive agreement to acquire ortho clinical diagnostics. Provides Quidel’s expansive point-of-care diagnostics portfolio with access to Ortho’s broad global reach across 130-plus countries, accelerating growth for Quidel’s existing product portfolio and providing exposure to new, emerging markets
In Feb 2019, bioMérieux, an in vitro diagnostics and food microbiology testing company, announced the acquisition of Invisible Sentinel. This newly acquired company, based in Philadelphia, develops, manufactures, and markets molecular diagnostic tools for the rapid, accurate and reliable detection of pathogens and spoilage organisms in food and beverage.